MANNEDORF, SWITZERLAND--(Marketwire - Mar 7, 2013) - Tecan Group AG /
Tecan's OEM partner Dako unveils new platform at global congress
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
The Tecan Group (SIX Swiss Exchange: TECN) announced today that its OEM partner Dako, an Agilent Technologies
and worldwide provider of cancer diagnostics, unveiled the new advanced
platform at the 2013 USCAP congress in Baltimore, Maryland, USA. Earlier
week, it was presented to a global gathering of pathologists and lab
for the first time.
In May 2011, Tecan signed a major OEM agreement with Dako for the
and supply of an advanced staining platform. Formerly the development
was referred to by Tecan as P16. The solution, Dako Omnis, comprises
software and reagents.
Lars Holmkvist, CEO of Dako said: "The Dako Omnis offers full-automation to
satisfy the needs of large-scale laboratories, hospitals and universities.
has been our ideal development partner for this system due to their strong
application know-how and experience with end-customer workflows in the IHC
ISH segment. Furthermore, as we progressed through the development, we
that Tecan shared our values of innovation and ownership and that their
experience in system integration was key in bringing the Dako OMNIS to
Tecan CEO David Martyr commented: "We are delighted to work with Dako, a
leader in the fast growing area of tissue-based cancer diagnostics. The
Omnis is really setting a new standard for advanced staining. We expect
volumes for Tecan from the supply of the Dako Omnis to accelerate from the
second half of this year with a substantial contribution to our sales
from 2014 onwards. Based on our partnership today, we look forward to
intensify our relationship with Dako in the future."
Methods used in the diagnosis of abnormal cells such as those found in
tumors include immunohistochemistry (IHC) and in situ hybridization (ISH).
Dako Omnis automates both IHC and ISH processes, meaning entire patient
can be processed simultaneously. This allows pathologists to make quicker,
informed diagnoses. Oncologists can in turn prescribe relevant therapy with
anxiety-ridden waiting time for patients.
With continuous loading, batch loading and overnight run options all
Dako Omnis sets new standards for what customers can expect from an
platform in terms of flexibility, capacity, efficiency and traceability of
slides. The platform provides state-of-the-art software to bring lab
a new level. Now, key processes such as slide processing and instrument
maintenance can be traced to individual operators, greatly increasing
Tecan (www.tecan.com) is a leading global provider of laboratory
solutions in biopharmaceuticals, forensics and clinical diagnostics. The
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales
service network in 52 countries. In 2012, Tecan generated sales of
CHF 391 million (USD 416 million; EUR 323 million). Registered shares of
Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE